entacapone mylan
mcdermott laboratories ltd t/a gerard laboratories - entacapone - film coated tablet - 200 milligram
comtan
orion pharma (nz) limited - entacapone 200mg - film coated tablet - 200 mg - active: entacapone 200mg excipient: croscarmellose sodium ethanol glycerol hydrogenated vegetable oil hypromellose iron oxide red iron oxide yellow magnesium stearate mannitol microcrystalline cellulose polysorbate 80 purified water sucrose titanium dioxide - entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilized on those combinations.
stalevo 10025200 mg
inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.
stalevo 7518.75200
inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - film coated tablets - carbidopa as monohydrate 18.75 mg; entacapone 200 mg; levodopa 75 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.
stalevo 12531.25200 mg
inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - film coated tablets - levodopa 125 mg; entacapone 200 mg; carbidopa as monohydrate 31.25 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.
stalevo 5012.5200 mg
inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.
stalevo 15037.5200 mg
inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 150 mg; carbidopa 37.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.
entacapone mylan 200 milligram film coated tablet
mcdermott laboratories ltd t/a gerard laboratories - entacapone - film coated tablet - 200 milligram
ventolin i.m. injection 0.5mg salbutamol in 1 ml (500mcg/ml) solution
glaxosmithkline inc - salbutamol (salbutamol sulfate) - solution - 0.5mg - salbutamol (salbutamol sulfate) 0.5mg - selective beta 2-adrenergic agonists
ventolin i.v. infusion solution 5.0mg salbutamol in 5ml (1000mcg/ml)
glaxosmithkline inc - salbutamol (salbutamol sulfate) - solution - 1mg - salbutamol (salbutamol sulfate) 1mg - selective beta 2-adrenergic agonists